Article
Oncology
Michelle McMullen, Ainhoa Madariaga, Stephanie Lheureux
Summary: Platinum drugs are crucial in ovarian cancer treatment, but resistance is a major challenge, with complex mechanisms involving both intracellular and microenvironment factors. Clinical trials are essential for improving outcomes, and future research should focus on understanding the biology of the disease and enhancing quality of life and survival for patients.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
M. Cummings, C. Freer, N. M. Orsi
Summary: Ovarian cancer often presents at an advanced stage and initial response to platinum-based therapies is positive, but chemoresistance develops leading to poor prognosis. The tumor microenvironment has been found to play a central role in therapy resistance and disease progression, making it an attractive therapeutic target. Focus has been on targeting cancer associated fibroblasts, tumor-associated macrophages, cancer stem cells, and cancer cell metabolic vulnerabilities for new therapies.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Nanoscience & Nanotechnology
Mengjun Zhang, Haodi Yue, Xin Huang, Jialin Wang, Zengbei Li, Xinjie Deng
Summary: This study demonstrates the anti-tumor effects of polyethylenimine-caged platinum nanoclusters on cisplatin-resistant ovarian cancer cells, inhibiting proliferation and migration while promoting apoptosis. The study also validates the role of these nanoclusters in regulating autophagy through the PI3K-AKT-mTOR signaling pathway. These findings suggest the promising potential of platinum nanoclusters as a novel chemotherapeutic agent for cisplatin-resistant ovarian cancer.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Oncology
Hiroki Nasu, Shin Nishio, Jongmyung Park, Teruyuki Yoshimitsu, Ken Matsukuma, Kazuto Tasaki, Takahiro Katsuda, Atsumu Terada, Naotake Tsuda, Kimio Ushijima
Summary: This study evaluated the efficacy and safety of gemcitabine and carboplatin with or without bevacizumab in patients with platinum-resistant ovarian cancer (PROC). The results showed that GC +/- B may be an effective and safe treatment alternative for PROC, especially for patients with a platinum-free interval of 3-6 months.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Jing Cui, Yao Guo, Heshui Wu, Jiongxin Xiong, Tao Peng
Summary: The study found that everolimus (Evr) can overcome gemcitabine (GEM) resistance in pancreatic cancer by inhibiting aerobic glycolysis and promoting apoptosis. The therapeutic effect of Evr in GEM-resistant cells was significantly better than in GEM-sensitive cells.
MOLECULAR MEDICINE
(2021)
Article
Oncology
Tanya Singh, Adam Neal, Gabriella Dibernardo, Neela Raheseparian, Neda A. Moatamed, Sanaz Memarzadeh
Summary: Our study demonstrates that combination therapy with birinapant and carboplatin can target a subset of platinum-resistant ovarian cancers, and also highlights the potential of the 3D organoid bioassay as a preclinical tool to assess the response to chemotherapy or targeted therapies in ovarian cancer.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Linlin Qu, Yannan Liu, Jianjun Deng, Xiaoxuan Ma, Daidi Fan
Summary: Ginsenoside Rk3, derived from heat-treated ginseng, has been found to inhibit the proliferation of hepatocellular carcinoma (HCC) by regulating the PI3K/AKT pathway and promoting autophagy and apoptosis. This discovery provides valuable insights for the development of novel therapeutic strategies targeting the PI3K/AKT pathway for HCC treatment.
JOURNAL OF PHARMACEUTICAL ANALYSIS
(2023)
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Platinum-resistant ovarian cancer is associated with poor prognosis and limited treatment options. Combination treatment with immunotherapy, anti-angiogenic therapy, and chemotherapy can significantly extend progression-free survival in these patients.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Ovarian cancer is a common gynecologic cancer in the US, and platinum-resistant disease has a poor prognosis. This study suggests that treatment with immunotherapy followed by anti-angiogenic therapy and chemotherapy can improve survival in patients with platinum-resistant ovarian cancer. The experience of three patients showed significantly longer progression-free survival compared to previous averages.
Review
Oncology
Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang
Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.
Article
Pharmacology & Pharmacy
Zhoupeng Li, Fang Wang, Yongsheng Liu, Dongshen Zhai, Xiaoxiao Zhang, Qikang Ying, Min Jia, Xiaoyan Xue, Jingru Meng, Jing Li, Xingan Wu, Mingkai Li
Summary: A study found that the coumarin derivative N6 shows strong inhibitory effects on HTNV, and early administration can effectively inhibit virus replication and production. Molecular docking results show that N6 interacts with key amino acid residues, and the treatment can inhibit the expression of specific proteins.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Alice Indini, Olga Nigro, Csongor Gyorgy Lengyel, Michele Ghidini, Angelica Petrillo, Salvatore Lopez, Francesco Raspagliesi, Dario Trapani, Shelize Khakoo, Giorgio Bogani
Summary: Patients with platinum-resistant ovarian cancer have a poor prognosis with limited treatment options. While single-agent immunotherapy has shown disappointing results, combining immunotherapy with target therapies like PARP inhibitors and TKIs appears promising. Ongoing trials are evaluating these combination strategies to assess their impact and cost-effectiveness.
Article
Oncology
Panagiotis A. Konstantinopoulos, Jung-Min Lee, Bo Gao, Rowan Miller, Jung-Yun Lee, Nicoletta Colombo, Ignace Vergote, Kelly M. Credille, Suzanne R. Young, Samuel McNeely, Xuejing Aimee Wang, Aimee Bence Lin, Ronnie Shapira-Frommer
Summary: This study aimed to evaluate the efficacy and safety of using prexasertib, a CHK1 inhibitor, in treating high-grade serous ovarian cancer. The results showed that prexasertib demonstrated durable single agent activity to a certain extent and its effects were not influenced by clinical characteristics, BRCA status, or prior therapies, including PARPi. The study also emphasized the need for alternative biomarker approaches to identify responders.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Jianxiu Duan, Mingyuan Yin, Yaqin Shao, Jiao Zheng, Shengdan Nie
Summary: Puerarin demonstrates effective inhibition of platinum-resistant ovarian cancer cell growth and induces apoptosis, as well as enhances sensitivity to chemotherapy. This effect is achieved through downregulation of SIRT1 and subsequent inhibition of Wnt/beta-catenin signaling.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii
Summary: Ovarian cancer is the second leading cause of death in women with gynecological cancer, with poor prognosis, especially in platinum-resistant disease. Efforts have been made to define new biomarkers, with circulating biomarkers being detected non-invasively but potentially requiring expensive techniques.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)